Editor’s Note Archive

Under threat of an interim order from the Supreme Court, the Group of Ministers (GoM) tasked with framing India's drug pricing…

On a day that saw one vaccine major announce a major collaboration in the generic and branded pharma space, another player…

The debate on patents vs patients remains on the boil, with the Bayer/ Nexavar and Novartis/ Gleevec cases keeping the issue live.…

With the London 2012 Olympics just behind us, we don't need to be reminded that being first counts.

Policy makers in India need to adapt fast to new realities and move forward like other global regulators

The release of guidelines for biosimilar drugs in India reportedly created a buzz at last month’s BIO meet at Boston. The 52-page…

In a landmark judgement, 'Obamacare', President Barack Obama's reform of the US healthcare system, won by a close 5-4 vote in the…

Tuberculosis, once known as a poor man’s illness, today shows no class discrimination. Bollywood super stars, top performing super…

First the good news. The BSE Healthcare Index has outperformed the overall Sensex in the last two years. Indian pharmaceutical…

At the recently concluded World Health Assembly in Geneva, one of the hotly debated topics was the adoption of a global Convention…